Viz.ai Sells Workflow Access to Pharma

This turns Viz.ai from a hospital software vendor into a toll collector on clinical attention. Once Viz.ai is embedded in stroke, cardiology, oncology, and other urgent workflows, drug makers can pay to surface the right patient, care step, or therapy support inside the same screens clinicians already use to review scans, coordinate consults, and move a patient to treatment. That is a much harder asset to copy than an alerting algorithm alone.1 2 3 4 5

• Viz.ai had expanded to about 1,700 hospitals by January 2025 and nearly 2,000 hospitals by January 2026, while its life sciences partnerships rose from 10 to 13 over that period. The pitch to pharma is simple, access to a large installed network where patient identification and care coordination already happen in real time.2 1 3
• What pharma is buying is not generic advertising. Viz.ai plugs into EHR, PACS, and radiology workflow, so a COPD, cancer, or stroke program can trigger when imaging or chart data suggests an eligible patient, then route the case to the right specialist, navigator, or follow up step without asking the hospital to adopt a separate tool.6 7 5 8
• This creates a second revenue stream beyond hospital subscriptions. It also makes Viz.ai more defensible than workflow only competitors like Pulsara, because pharma partners care less about messaging alone and more about whether the software sits in the exact handoff where diagnosis, referral, and treatment start.4 5

The next step is likely deeper commercialization of this network as a clinical distribution layer for specialty therapies. As Viz.ai adds more disease programs and more health system integrations, more drug launches can be built on top of the same workflow rails, which should increase partner count, wallet share, and strategic value to both providers and life sciences companies.1 3 4 5